Nephrotoxicity of targeted therapy used to treat lung cancer

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Lung cancer, particularly non-small cell lung cancer, remains a leading cause of cancer mortality globally.
• Targeted therapies offer improved prognoses by inhibiting specific cancer-promoting genes, but present unique toxicities.
• Drug-related nephrotoxicity is an emerging concern in cancer treatment.

Purpose of the Study:

• To review the adverse renal effects of targeted therapies in lung cancer.
• To focus on toxicities associated with Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors.
• To discuss potential mechanisms of nephrotoxicity and propose clinical management strategies.

Main Methods:

• Literature review of studies on targeted therapy-induced nephrotoxicity in lung cancer.
• Analysis of adverse event data related to EGFR and ALK inhibitors.
• Synthesis of information on renal side effect mechanisms and management.

Main Results:

• Targeted therapies, especially EGFR and ALK inhibitors, are associated with various adverse renal effects.
• Understanding the specific mechanisms of these toxicities is crucial for effective management.
• Early recognition and appropriate interventions can help mitigate kidney damage.

Conclusions:

• Adverse renal effects from targeted lung cancer therapies require careful monitoring and management.
• Specific management strategies can improve renal function and patient outcomes.
• Further research into the mechanisms and prevention of drug-induced nephrotoxicity is warranted.